
Results
70
70 companies
Madrigal Pharmaceuticals
Market Cap: US$11.9b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$517.26
7D
-1.0%
1Y
93.3%
Zevra Therapeutics
Market Cap: US$592.9m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$10.03
7D
-3.8%
1Y
16.0%
Oscotec
Market Cap: ₩1.6t
Operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses.
A039200
₩42,250.00
7D
-10.5%
1Y
58.8%
Syndax Pharmaceuticals
Market Cap: US$1.8b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$19.94
7D
2.7%
1Y
102.4%
Starpharma Holdings
Market Cap: AU$271.6m
A biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally.
SPL
AU$0.65
7D
17.3%
1Y
616.7%
Camurus
Market Cap: SEK 31.4b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 538.50
7D
6.0%
1Y
4.1%
HansBiomed
Market Cap: ₩410.7b
Engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies.
A042520
₩28,800.00
7D
20.5%
1Y
250.8%
Bonesupport Holding
Market Cap: SEK 16.9b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 263.20
7D
8.8%
1Y
-2.1%
AnaptysBio
Market Cap: US$1.7b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$59.71
7D
1.7%
1Y
192.1%
Ardelyx
Market Cap: US$1.5b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$6.11
7D
0%
1Y
53.9%
Cutia Therapeutics
Market Cap: HK$1.5b
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
2487
HK$4.16
7D
-0.7%
1Y
-49.6%
Ocumension Therapeutics
Market Cap: HK$5.1b
Operates as an ophthalmic pharmaceutical platform company in the People's Republic of China.
1477
HK$6.24
7D
-4.7%
1Y
-13.5%
ARS Pharmaceuticals
Market Cap: US$788.5m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$7.94
7D
8.8%
1Y
-47.0%
Lineage Cell Therapeutics
Market Cap: US$324.1m
A clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.
LCTX
US$1.30
7D
4.8%
1Y
86.1%
Capricor Therapeutics
Market Cap: US$1.7b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$28.87
7D
3.1%
1Y
181.7%
Intellia Therapeutics
Market Cap: US$1.8b
Operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
NTLA
US$12.60
7D
-0.7%
1Y
37.6%
Aldeyra Therapeutics
Market Cap: US$93.5m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.55
7D
-3.1%
1Y
-30.2%
Bide Pharmatech
Market Cap: CN¥4.8b
Engages in the research, development, production, and sale of pharmaceutical products in China.
688073
CN¥55.44
7D
2.2%
1Y
31.4%
Clinuvel Pharmaceuticals
Market Cap: AU$447.3m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$8.87
7D
-2.8%
1Y
-15.0%
Imexpharm
Market Cap: ₫7.1t
Operates as a pharmaceutical company in Vietnam.
IMP
₫46,300.00
7D
0.1%
1Y
-15.4%
Pharma Mar
Market Cap: €1.7b
A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally.
PHM
€101.50
7D
5.6%
1Y
16.2%
AC Immune
Market Cap: US$280.7m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$2.83
7D
2.2%
1Y
67.5%
Arcutis Biotherapeutics
Market Cap: US$2.6b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$20.86
7D
4.1%
1Y
49.2%
CG Oncology
Market Cap: US$5.7b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$64.25
7D
2.1%
1Y
152.6%
May & Baker Nigeria
Market Cap: ₦86.3b
May & Baker Nigeria Plc, together with its subsidiaries, manufactures, sells, and distributes human pharmaceuticals, human vaccines, and consumer products in Nigeria.
MAYBAKER
₦50.00
7D
5.7%
1Y
323.7%
Oxford Biomedica
Market Cap: UK£747.3m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£6.18
7D
1.5%
1Y
93.1%
BioStem Technologies
Market Cap: US$70.1m
Engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
BSEM
US$4.14
7D
-6.2%
1Y
-65.5%
Bora Pharmaceuticals
Market Cap: NT$46.5b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$366.50
7D
-5.5%
1Y
-43.3%
Belite Bio
Market Cap: US$5.4b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.
BLTE
US$137.30
7D
-3.9%
1Y
125.1%
Kuros Biosciences
Market Cap: CHF 852.5m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 21.76
7D
8.2%
1Y
-12.9%
Insmed
Market Cap: US$23.0b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$106.24
7D
-0.8%
1Y
57.3%
Neurocrine Biosciences
Market Cap: US$15.8b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$156.70
7D
-0.3%
1Y
30.4%
SIGA Technologies
Market Cap: US$335.7m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$4.68
7D
9.6%
1Y
-20.8%
NewAmsterdam Pharma
Market Cap: US$4.1b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
NAMS
US$35.44
7D
3.8%
1Y
101.2%
Genovis AB (publ.)
Market Cap: SEK 1.4b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 20.55
7D
2.8%
1Y
-22.2%
Devyser Diagnostics
Market Cap: SEK 1.6b
Provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa.
DVYSR
SEK 99.70
7D
10.7%
1Y
-0.5%